Serum REG3α Flags Crohn's Disease Progression Risk

A study of 394 patients links high blood levels of the protein REG3α to worsening Crohn's disease, independent of standard inflammation markers.

Updated on Nov. 19, 2026 in Diseases — General

Row of clear glass vials holding pale amber fluid on a bare stainless laboratory bench under cool side light, with one centrifuge tube catching the light.
Researchers found high blood levels of the protein REG3α independently predict Crohn's disease progression in a study of 394 patients across Mount Sinai and Leuven. AI Illustration. Upload story photo >

Researchers found that high serum REG3α independently predicts progression of Crohn's disease, even in patients with mild or inactive disease. The association held across cohorts at Mount Sinai and Leuven.

Why it matters

Current monitoring relies on markers such as C-reactive protein and endoscopic findings, which may not capture everyone at risk. A noninvasive blood biomarker could help clinicians identify patients who need closer follow-up before complications develop.

The study combined two cross-sectional cohorts and a prediagnostic cohort totaling 394 patients, with hazard ratios of 1.9 at Mount Sinai and 2.9 at Leuven for high serum REG3α and disease progression. Whether these associations translate into improved clinical decisions has not been established.

The details

Researchers measured serum REG3α and tissue REG3α expression, the latter assessed by bulk RNA sequencing of paired ileal and colonic biopsies. Progression was defined as hospitalization, surgery, steroid course, or new advanced therapy, and high serum levels remained associated with progression in patients with mild or inactive disease. In a prediagnostic cohort, elevated levels predicted Crohn's disease, particularly complicated and surgical forms, up to 10 years before diagnosis.

Timeline

  1. Elevated serum REG3α was seen up to 10 years before diagnosis in patients who later developed complicated disease.

Health Landscape

The finding builds on research showing Crohn's disease is associated with loss of regenerative Paneth cells and enrichment of REG3α-expressing cell populations. It moves that biological observation toward a potential noninvasive tool for stratifying patient risk.

If validated, a routine blood test could help patients with mild or quiet Crohn's disease learn their risk of progression sooner. Anyone managing the condition should continue following their clinician's current monitoring plan until such tests are available.

The takeaway

Blood markers such as serum REG3α may eventually complement standard tests in tracking Crohn's disease. Patients should keep discussing monitoring options with their care team rather than changing treatment based on early research.

Further reading

Explore more on Diseases — General for broader context on chronic inflammatory conditions like Crohn's disease.

Source note: This article includes information reported by Derm Immuno Today.